Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology  

作　　者：Xue, Xue Liang, Xing-Jie 

机构地区：[1]Natl Ctr Nanosci & Technol China, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China

出　　处：《Chinese Journal of Cancer》2012年第2期100-109,共10页

基　　金：supported by the National Key Basic Research Program of China(973projects2009CB930200);the program of National Natural Science Foundation of China(30970784and81171455);the support of the Chinese Academy of Sciences(CAS)"Hundred Talents Program"and CAS Knowledge Innovation Program

摘　　要：Multidrug resistance(MDR),which significantly decreases the efficacy of anticancer drugs and causes tumor recurrence,has been a major challenge in clinical cancer treatment with chemotherapeutic drugs for decades.Several mechanisms of overcoming drug resistance have been postulated.Well known P-glycoprotein(P-gp) and other drug efflux transporters are considered to be critical in pumping anticancer drugs out of cells and causing chemotherapy failure.Innovative theranostic(therapeutic and diagnostic) strategies with nanoparticles are rapidly evolving and are anticipated to offer opportunities to overcome these limits.In this review,we discuss the mechanisms of drug efflux-mediated resistance and the application of multiple nanoparticle-based platforms to overcome chemoresistance and improve therapeutic outcome.Multidrug resistance （MDR）, which significantly decreases the efficacy of anticancer drugs and causes tumor recurrence, has been a major challenge in clinical cancer treatment with chemotherapeutic drugs for decades. Several mechanisms of overcoming drug resistance have been postulated. Well known P-glycoprotein （P-gp） and other drug efflux transporters are considered to be critical in pumping anticancer drugs out of cells and causing chemotherapy failure. Innovative theranostic （therapeutic and diagnostic） strategies with nanoparticles are rapidly evolving and are anticipated to offer opportunities to overcome these limits. In this review, we discuss the mechanisms of drug efflux-mediated resistance and the application of multiple nanoparticle-based platforms to overcome chemoresistance and improve therapeutic outcome.

关 键 词：抗癌药物 多药耐药 纳米技术 外排 癌症 P-糖蛋白 临床治疗 化疗药物 

分 类 号：S791.49[农业科学—林木遗传育种] Q51[农业科学—林学]